Ensysce Biosciences (NASDAQ:ENSC) Issues Quarterly Earnings Results, Beats Estimates By $0.37 EPS

Ensysce Biosciences (NASDAQ:ENSC) issued its quarterly earnings results on Tuesday. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.30) by $0.37, Zacks reports. The company had revenue of $3.42 million during the quarter, compared to analysts’ expectations of $0.25 million. Ensysce Biosciences had a negative net margin of 179.26% and a negative return on equity of 559.68%.

Ensysce Biosciences Stock Down 10.3 %

NASDAQ ENSC traded down $0.07 on Thursday, reaching $0.64. The company had a trading volume of 3,081,125 shares, compared to its average volume of 8,568,815. Ensysce Biosciences has a 52 week low of $0.14 and a 52 week high of $2.06. The stock has a market cap of $5.61 million, a price-to-earnings ratio of -0.35 and a beta of 0.63. The stock’s 50 day moving average is $0.37 and its 200-day moving average is $0.45.

About Ensysce Biosciences

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.